Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.

Gooderham M, Guttman-Yassky E, Igawa K, Kabashima K, Esfandiari E, Rylands AJ, Williams A, Nixon A, Dent JE, Simpson E.

Open source

DOI
10.1007/s13555-024-01303-z
Published
2024-11-12
Container
Dermatol Ther (Heidelb)
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s13555-024-01303-z,
  title = {Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.},
  author = {Gooderham M and  Guttman-Yassky E and  Igawa K and  Kabashima K and  Esfandiari E and  Rylands AJ and  Williams A and  Nixon A and  Dent JE and  Simpson E.},
  year = {2024},
  journal = {Dermatol Ther (Heidelb)},
  doi = {10.1007/s13555-024-01303-z},
  url = {https://doi.org/10.1007/s13555-024-01303-z}
}

RIS

TY  - JOUR
TI  - Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.
AU  - Gooderham M
AU  -  Guttman-Yassky E
AU  -  Igawa K
AU  -  Kabashima K
AU  -  Esfandiari E
AU  -  Rylands AJ
AU  -  Williams A
AU  -  Nixon A
AU  -  Dent JE
AU  -  Simpson E.
PY  - 2024
JO  - Dermatol Ther (Heidelb)
DO  - 10.1007/s13555-024-01303-z
UR  - https://doi.org/10.1007/s13555-024-01303-z
ER  - 

APA

M, G., E, G., K, I., K, K., E, E., AJ, R., A, W., A, N., JE, D., & E., S. (2024). Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.. Dermatol Ther (Heidelb). https://doi.org/10.1007/s13555-024-01303-z

Source records